Olema Ebitda vs Research Development Analysis

OLMA Stock

USD 12.62 0.36 2.77%

Olema Pharmaceuticals financial indicator trend analysis is much more than just breaking down Olema Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Olema Pharmaceuticals is a good investment. Please check the relationship between Olema Pharmaceuticals Ebitda and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

Ebitda vs Research Development

Ebitda vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Olema Pharmaceuticals Ebitda account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Olema Pharmaceuticals' Ebitda and Research Development is -0.97. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Research Development in the same time period over historical financial statements of Olema Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Olema Pharmaceuticals' Ebitda and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Olema Pharmaceuticals are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebitda i.e., Olema Pharmaceuticals' Ebitda and Research Development go up and down completely randomly.

Correlation Coefficient

-0.97

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebitda

Research Development

Most indicators from Olema Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Olema Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.At present, Olema Pharmaceuticals' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 808.9 M, whereas Selling General Administrative is forecasted to decline to about 13.3 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.7M	357K	377K	445.9K
Interest Income	442K	2.2M	5.7M	6.0M

Depreciation And Amortization Interest Income

Olema Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Common Stock Total Equity
Total Assets		0.64	0.74	1.0	1.0	0.74	-0.82	-0.69	0.52	0.85	0.75	0.68	0.53	1.0	0.84	-0.97	0.57	0.96	0.39	1.0	0.73	1.0	1.0	0.96	0.68	-0.4
Other Current Liab	0.64		0.96	0.62	0.58	0.64	-0.11	-0.97	0.85	0.2	0.84	0.88	0.0	0.62	0.7	-0.78	0.98	0.78	0.8	0.62	0.64	0.63	0.6	0.79	0.35	-0.79
Total Current Liabilities	0.74	0.96		0.73	0.7	0.79	-0.26	-0.99	0.83	0.35	0.95	0.95	-0.02	0.73	0.79	-0.85	0.94	0.87	0.8	0.73	0.79	0.74	0.71	0.87	0.58	-0.79
Total Stockholder Equity	1.0	0.62	0.73		1.0	0.73	-0.84	-0.67	0.5	0.86	0.73	0.67	0.55	1.0	0.83	-0.97	0.54	0.95	0.36	1.0	0.72	1.0	1.0	0.95	0.67	-0.39
Net Tangible Assets	1.0	0.58	0.7	1.0		0.72	-0.86	-0.64	0.46	0.88	0.71	0.63	0.57	1.0	0.82	-0.96	0.51	0.93	0.32	1.0	0.71	1.0	1.0	0.93	0.67	-0.35
Property Plant And Equipment Net	0.74	0.64	0.79	0.73	0.72		-0.41	-0.78	0.39	0.44	0.89	0.74	-0.14	0.73	0.72	-0.77	0.69	0.83	0.71	0.73	1.0	0.73	0.72	0.82	0.91	-0.36
Net Debt	-0.82	-0.11	-0.26	-0.84	-0.86	-0.41		0.19	-0.12	-0.99	-0.35	-0.27	-0.73	-0.83	-0.57	0.7	-0.01	-0.63	0.17	-0.84	-0.4	-0.83	-0.85	-0.63	-0.56	0.05
Retained Earnings	-0.69	-0.97	-0.99	-0.67	-0.64	-0.78	0.19		-0.84	-0.28	-0.95	-0.96	0.08	-0.68	-0.75	0.81	-0.95	-0.84	-0.85	-0.67	-0.77	-0.68	-0.66	-0.85	-0.55	0.8
Accounts Payable	0.52	0.85	0.83	0.5	0.46	0.39	-0.12	-0.84		0.22	0.74	0.88	0.04	0.51	0.67	-0.61	0.75	0.62	0.64	0.5	0.36	0.51	0.49	0.65	0.23	-0.91
Cash	0.85	0.2	0.35	0.86	0.88	0.44	-0.99	-0.28	0.22		0.43	0.36	0.71	0.86	0.61	-0.75	0.09	0.66	-0.13	0.86	0.43	0.85	0.87	0.67	0.58	-0.18
Non Current Assets Total	0.75	0.84	0.95	0.73	0.71	0.89	-0.35	-0.95	0.74	0.43		0.96	-0.12	0.74	0.76	-0.82	0.83	0.86	0.77	0.73	0.88	0.74	0.72	0.86	0.78	-0.74
Non Currrent Assets Other	0.68	0.88	0.95	0.67	0.63	0.74	-0.27	-0.96	0.88	0.36	0.96		-0.1	0.67	0.72	-0.77	0.84	0.8	0.76	0.67	0.72	0.67	0.66	0.81	0.62	-0.87
Other Assets	0.53	0.0	-0.02	0.55	0.57	-0.14	-0.73	0.08	0.04	0.71	-0.12	-0.1		0.54	0.3	-0.44	-0.12	0.32	-0.42	0.55	-0.14	0.54	0.56	0.33	-0.12	0.1
Cash And Short Term Investments	1.0	0.62	0.73	1.0	1.0	0.73	-0.83	-0.68	0.51	0.86	0.74	0.67	0.54		0.84	-0.97	0.55	0.95	0.37	1.0	0.72	1.0	1.0	0.95	0.67	-0.4
Common Stock Shares Outstanding	0.84	0.7	0.79	0.83	0.82	0.72	-0.57	-0.75	0.67	0.61	0.76	0.72	0.3	0.84		-0.86	0.65	0.86	0.55	0.83	0.71	0.84	0.83	0.86	0.6	-0.48
Non Current Liabilities Total	-0.97	-0.78	-0.85	-0.97	-0.96	-0.77	0.7	0.81	-0.61	-0.75	-0.82	-0.77	-0.44	-0.97	-0.86		-0.72	-0.97	-0.49	-0.97	-0.77	-0.97	-0.97	-0.97	-0.64	0.53
Other Current Assets	0.57	0.98	0.94	0.54	0.51	0.69	-0.01	-0.95	0.75	0.09	0.83	0.84	-0.12	0.55	0.65	-0.72		0.74	0.85	0.54	0.7	0.56	0.53	0.74	0.37	-0.72
Other Stockholder Equity	0.96	0.78	0.87	0.95	0.93	0.83	-0.63	-0.84	0.62	0.66	0.86	0.8	0.32	0.95	0.86	-0.97	0.74		0.64	0.95	0.83	0.95	0.94	1.0	0.69	-0.49
Total Liab	0.39	0.8	0.8	0.36	0.32	0.71	0.17	-0.85	0.64	-0.13	0.77	0.76	-0.42	0.37	0.55	-0.49	0.85	0.64		0.36	0.7	0.37	0.34	0.63	0.44	-0.52
Net Invested Capital	1.0	0.62	0.73	1.0	1.0	0.73	-0.84	-0.67	0.5	0.86	0.73	0.67	0.55	1.0	0.83	-0.97	0.54	0.95	0.36		0.72	1.0	1.0	0.95	0.67	-0.39
Property Plant And Equipment Gross	0.73	0.64	0.79	0.72	0.71	1.0	-0.4	-0.77	0.36	0.43	0.88	0.72	-0.14	0.72	0.71	-0.77	0.7	0.83	0.7	0.72		0.72	0.71	0.81	0.89	-0.35
Total Current Assets	1.0	0.63	0.74	1.0	1.0	0.73	-0.83	-0.68	0.51	0.85	0.74	0.67	0.54	1.0	0.84	-0.97	0.56	0.95	0.37	1.0	0.72		1.0	0.95	0.67	-0.4
Net Working Capital	1.0	0.6	0.71	1.0	1.0	0.72	-0.85	-0.66	0.49	0.87	0.72	0.66	0.56	1.0	0.83	-0.97	0.53	0.94	0.34	1.0	0.71	1.0		0.94	0.67	-0.38
Common Stock	0.96	0.79	0.87	0.95	0.93	0.82	-0.63	-0.85	0.65	0.67	0.86	0.81	0.33	0.95	0.86	-0.97	0.74	1.0	0.63	0.95	0.81	0.95	0.94		0.68	-0.51
Property Plant Equipment	0.68	0.35	0.58	0.67	0.67	0.91	-0.56	-0.55	0.23	0.58	0.78	0.62	-0.12	0.67	0.6	-0.64	0.37	0.69	0.44	0.67	0.89	0.67	0.67	0.68		-0.25
Common Stock Total Equity	-0.4	-0.79	-0.79	-0.39	-0.35	-0.36	0.05	0.8	-0.91	-0.18	-0.74	-0.87	0.1	-0.4	-0.48	0.53	-0.72	-0.49	-0.52	-0.39	-0.35	-0.4	-0.38	-0.51	-0.25

Click cells to compare fundamentals

Olema Pharmaceuticals Account Relationship Matchups

Olema Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	132K	342.7M	295.9M	215.6M	276.9M	208.0M
Other Current Liab	443K	3.9M	378K	15.2M	17.9M	18.8M
Total Current Liabilities	1.4M	4.6M	9.0M	16.5M	21.6M	22.7M
Total Stockholder Equity	(10.6M)	338.1M	284.6M	197.5M	253.9M	193.8M
Net Tangible Assets	(10.6M)	338.1M	284.6M	197.5M	227.2M	176.7M
Net Debt	(68K)	(338.5M)	(284.0M)	(21.1M)	(66.1M)	(69.4M)
Retained Earnings	(10.8M)	(33.1M)	(104.2M)	(209.0M)	(305.6M)	(290.4M)
Accounts Payable	935K	719K	23K	374K	2.7M	2.8M
Cash	68K	338.5M	287.3M	23.7M	68.5M	132.2M
Cash And Short Term Investments	68K	338.5M	287.3M	204.4M	261.8M	200.8M
Common Stock Shares Outstanding	40.2M	39.3M	39.5M	40.0M	45.2M	40.0M
Liabilities And Stockholders Equity	132K	342.7M	295.9M	215.6M	276.9M	208.0M
Other Current Assets	35K	149K	223K	4.5M	4.0M	4.2M
Other Stockholder Equity	168K	371.2M	388.9M	408.3M	559.2M	316.8M
Total Liab	10.7M	4.6M	11.4M	18.1M	23.1M	14.2M
Net Invested Capital	(10.6M)	338.1M	284.6M	197.5M	253.9M	193.8M
Total Current Assets	103K	342.1M	287.3M	208.9M	266.5M	203.2M
Accumulated Other Comprehensive Income	(9.3M)	(342.7M)	(149K)	(1.8M)	347K	364.4K
Net Working Capital	(1.3M)	337.6M	281.7M	192.4M	244.9M	194.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GM	General Motors
GM	General Motors
GOOG	Alphabet Inc Class C

Additional Information and Resources on Investing in Olema Stock

When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:

How To Invest In Olema

Details

Is Olema Stock a good investment?

Details

What is Olema Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.04)

Return On Assets

(0.35)

Return On Equity

(0.56)

The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Olema Ebitda vs Research Development Analysis

Ebitda vs Research Development

Ebitda vs Research Development Correlation Analysis

Correlation Coefficient

Ebitda

Research Development

Olema Pharmaceuticals fundamental ratios Correlations

Olema Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Olema Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Information and Resources on Investing in Olema Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Common Stock	- 0.97	Non Current Liabilities Total
Net Working Capital	- 0.97	Non Current Liabilities Total
Total Current Assets	- 0.97	Non Current Liabilities Total
Net Invested Capital	- 0.97	Non Current Liabilities Total